ONITT: A phase I study of nanoliposomal irinotecan with talazoparib or temozolomide in children and young adults with recurrent or refractory solid tumors. Promoting Resilience in Stress Management ...
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer This phase Ib study evaluated the safety and efficacy of paclitaxel plus navicixizumab, a ...
CAMBRIDGE, Mass., Jan. 15 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results